Q4 2022 13F Holders as of 12/31/2022
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
126M
-
Number of holders
-
150
-
Total 13F shares, excl. options
-
98.4M
-
Shares change
-
+31.6M
-
Total reported value, excl. options
-
$334M
-
Value change
-
+$100M
-
Put/Call ratio
-
1.4
-
Number of buys
-
90
-
Number of sells
-
-58
-
Price
-
$3.40
Significant Holders of Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share (KPTI) as of Q4 2022
179 filings reported holding KPTI - Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share as of Q4 2022.
Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share (KPTI) has 150 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 98.4M shares
of 126M outstanding shares and own 77.79% of the company stock.
Largest 10 shareholders include Avidity Partners Management LP (9.63M shares), BlackRock Inc. (8.51M shares), Rubric Capital Management LP (8.29M shares), STATE STREET CORP (8.29M shares), Palo Alto Investors LP (5.66M shares), VANGUARD GROUP INC (5.2M shares), ARMISTICE CAPITAL, LLC (3.85M shares), CITADEL ADVISORS LLC (3.71M shares), JACOBS LEVY EQUITY MANAGEMENT, INC (2.25M shares), and MARSHALL WACE, LLP (2.21M shares).
This table shows the top 150 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.